Oklo has secured non-dilutive funding from Meta Platforms to advance its Pike County, Ohio nuclear campus, including an upfront payment that accelerates its pathway to revenue. In parallel, the company signed an Other Transaction Agreement with the Department of Energy to build a pilot radioisotope facility under its Atomic Alchemy subsidiary, allowing Oklo to generate critical data for future NRC approvals. With over $300 million in cash and no debt on the balance sheet, these deals validate demand for its small modular reactors and underpin its integrated model of construction, generation and commercialization.

Institutional investors own 85% of Oklo’s shares, having increased their holdings through Q4 2025 and early 2026 at a ratio of roughly $3 purchased for every $1 sold. Short interest peaked near 15% at the end of 2025 but has declined steadily over three months following the stock’s pullback, suggesting reduced downside pressure. Analyst coverage has grown more than 300% year-over-year, with the majority of ratings and price-target revisions since November 2025 being bullish, resulting in a consensus forecast that implies upside potential.

Key milestones slated for 2026 include a criticality test at Los Alamos, submission of an NRC license application by year-end, and groundbreaking at the Ohio facility. Oklo also plans to demonstrate its fuel production and recycling technology through several ongoing projects. Management targets commercialization of its first reactors by early 2028, with meaningful earnings expected in 2030 and profitability achieved one to two years thereafter, setting the stage for hyper-growth in operating cash flow.